JP2022019973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022019973A5 JP2022019973A5 JP2021197319A JP2021197319A JP2022019973A5 JP 2022019973 A5 JP2022019973 A5 JP 2022019973A5 JP 2021197319 A JP2021197319 A JP 2021197319A JP 2021197319 A JP2021197319 A JP 2021197319A JP 2022019973 A5 JP2022019973 A5 JP 2022019973A5
- Authority
- JP
- Japan
- Prior art keywords
- activator
- manganese
- pharmaceutically acceptable
- acceptable salt
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012190 activator Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims 3
- -1 DPDP compound Chemical class 0.000 claims 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 3
- 231100000836 acute liver failure Toxicity 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052748 manganese Inorganic materials 0.000 claims 3
- 239000011572 manganese Substances 0.000 claims 3
- 229960005489 paracetamol Drugs 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 claims 2
- JFVHALAXWREODT-UHFFFAOYSA-N C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] Chemical compound C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] JFVHALAXWREODT-UHFFFAOYSA-N 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 1
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| JP2018555315A JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Division JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022019973A JP2022019973A (ja) | 2022-01-27 |
| JP2022019973A5 true JP2022019973A5 (enExample) | 2022-02-03 |
| JP7374163B2 JP7374163B2 (ja) | 2023-11-06 |
Family
ID=57909814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Active JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| JP2021197319A Active JP7374163B2 (ja) | 2016-01-11 | 2021-12-03 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555315A Active JP7311267B2 (ja) | 2016-01-11 | 2017-01-10 | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (enExample) |
| EP (2) | EP3842040B1 (enExample) |
| JP (2) | JP7311267B2 (enExample) |
| CN (1) | CN108601757A (enExample) |
| AU (1) | AU2017208123B2 (enExample) |
| CA (1) | CA3010915C (enExample) |
| RU (1) | RU2018128793A (enExample) |
| WO (1) | WO2017122120A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| CN113993529A (zh) * | 2019-05-21 | 2022-01-28 | 潘德勒姆治疗公司 | 用于治疗肝脏病症的方法和组合物 |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| WO2005017094A2 (en) | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| JP2008538586A (ja) | 2005-04-21 | 2008-10-30 | グレン エー． ゴールドスタイン， | 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
| JP2010507572A (ja) | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| RU2563825C2 (ru) * | 2009-07-06 | 2015-09-20 | Пледфарма Аб | Фармацевтические композиции и терапевтические способы, в которых применяется комбинация комплексного соединения марганца и соединения в форме, не являющейся марганцевым комплексом |
| ES2683038T3 (es) | 2012-01-05 | 2018-09-24 | Pledpharma Ab | Calmangafodipir, una nueva entidad química, y otros complejos metálicos mixtos, métodos de preparación, composiciones y métodos de tratamiento |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en active Active
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022019973A5 (enExample) | ||
| US10213420B2 (en) | Combination therapy for treatment of HBV infections | |
| US8114913B1 (en) | Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as smallpox and use in combination with DHEA for the treatment of smallpox | |
| US20210220353A1 (en) | Use of favipiravir in treatment of coronavirus infection | |
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| US20060189584A1 (en) | Pharmaceutical combinations | |
| JP2019501226A5 (enExample) | ||
| JP2009528367A (ja) | アレナウイルス感染の治療のための抗ウイルス薬剤 | |
| AU2002305952A1 (en) | Pharmaceutical combinations | |
| JPWO2020250915A5 (enExample) | ||
| US6281222B1 (en) | Compositions and method for treatment of acetaminophen intoxication | |
| US20250325503A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| CN115916178A (zh) | 非洲猪瘟(African Swine Fever:ASF)的治疗剂和/或预防剂 | |
| JPWO2020078905A5 (enExample) | ||
| KR20080096829A (ko) | 정맥내 항바이러스 치료 | |
| US20250197344A1 (en) | Compounds and methods for treatment of bacterial infections | |
| WO2025056747A1 (en) | Combination of a wee1 inhibitor and a pkmyt1 inhibitor | |
| CN1638767A (zh) | 包含埃坡霉素衍生物和烷化剂的组合 | |
| CA2120234A1 (en) | 2-aminopropan-1,3-diol chemotherapeutic agents | |
| WO2023237055A1 (zh) | 一种cdk4/6抑制剂治疗去分化脂肪肉瘤的用途 | |
| CN117752665A (zh) | 熊果酸作为柳氮磺吡啶抗肝癌增敏剂的用途 | |
| JPWO2022241134A5 (enExample) | ||
| HK40005150B (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide |